vs
Carter Bankshares, Inc.（CARE）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Carter Bankshares, Inc.的1.9倍（$75.5M vs $39.8M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 15.4%），Carter Bankshares, Inc.自由现金流更多（$31.8M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 9.1%）
卡特银行股份有限公司是美国区域性银行控股企业，旗下运营卡特银行与信托机构，提供零售及商业银行服务，包含存款账户、个人及商业贷款、财富管理等产品，主要服务弗吉尼亚州和北卡罗来纳州的本地居民及中小商业客户。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CARE vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.9倍
$39.8M
营收增速更快
PBYI
高出12.3%
15.4%
自由现金流更多
CARE
多$17.4M
$14.4M
两年增速更快
PBYI
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.8M | $75.5M |
| 净利润 | — | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 27.8% | 22.7% |
| 净利率 | — | — |
| 营收同比 | 15.4% | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.38 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAREPBYI
| Q4 25 | $39.8M | $75.5M | ||
| Q3 25 | $39.1M | $54.5M | ||
| Q2 25 | $37.3M | $52.4M | ||
| Q1 25 | $37.0M | $46.0M | ||
| Q4 24 | $34.5M | $59.1M | ||
| Q3 24 | $34.2M | $80.5M | ||
| Q2 24 | $33.6M | $47.1M | ||
| Q1 24 | $33.5M | $43.8M |
净利润CAREPBYI
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $8.8M | ||
| Q2 25 | $8.5M | $5.9M | ||
| Q1 25 | $9.0M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $5.6M | $20.3M | ||
| Q2 24 | $4.8M | $-4.5M | ||
| Q1 24 | $5.8M | $-4.8M |
毛利率CAREPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率CAREPBYI
| Q4 25 | 27.8% | 22.7% | ||
| Q3 25 | 18.3% | 17.6% | ||
| Q2 25 | 28.5% | 12.7% | ||
| Q1 25 | 30.1% | 8.7% | ||
| Q4 24 | 31.0% | 22.6% | ||
| Q3 24 | 20.5% | 27.4% | ||
| Q2 24 | 17.6% | -4.6% | ||
| Q1 24 | 21.6% | -5.3% |
净利率CAREPBYI
| Q4 25 | — | — | ||
| Q3 25 | 13.9% | 16.2% | ||
| Q2 25 | 22.8% | 11.2% | ||
| Q1 25 | 24.2% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 16.4% | 25.2% | ||
| Q2 24 | 14.3% | -9.6% | ||
| Q1 24 | 17.4% | -11.0% |
每股收益（稀释后）CAREPBYI
| Q4 25 | $0.38 | $0.26 | ||
| Q3 25 | $0.24 | $0.17 | ||
| Q2 25 | $0.37 | $0.12 | ||
| Q1 25 | $0.39 | $0.06 | ||
| Q4 24 | $0.36 | $0.40 | ||
| Q3 24 | $0.24 | $0.41 | ||
| Q2 24 | $0.21 | $-0.09 | ||
| Q1 24 | $0.25 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $419.7M | $130.3M |
| 总资产 | $4.9B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CAREPBYI
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | — | $107.2M |
总债务CAREPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益CAREPBYI
| Q4 25 | $419.7M | $130.3M | ||
| Q3 25 | $412.8M | $115.3M | ||
| Q2 25 | $405.6M | $104.7M | ||
| Q1 25 | $401.8M | $97.1M | ||
| Q4 24 | $384.3M | $92.1M | ||
| Q3 24 | $386.8M | $71.1M | ||
| Q2 24 | $364.4M | $48.5M | ||
| Q1 24 | $359.1M | $51.0M |
总资产CAREPBYI
| Q4 25 | $4.9B | $216.3M | ||
| Q3 25 | $4.8B | $202.9M | ||
| Q2 25 | $4.8B | $194.9M | ||
| Q1 25 | $4.7B | $196.2M | ||
| Q4 24 | $4.7B | $213.3M | ||
| Q3 24 | $4.6B | $220.7M | ||
| Q2 24 | $4.5B | $205.0M | ||
| Q1 24 | $4.6B | $214.1M |
负债/权益比CAREPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $39.9M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $31.8M | $14.4M |
| 自由现金流率自由现金流/营收 | 79.9% | 19.1% |
| 资本支出强度资本支出/营收 | 20.2% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $54.6M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CAREPBYI
| Q4 25 | $39.9M | $14.4M | ||
| Q3 25 | $11.8M | $9.7M | ||
| Q2 25 | $9.6M | $14.1M | ||
| Q1 25 | $6.4M | $3.6M | ||
| Q4 24 | $36.9M | $15.6M | ||
| Q3 24 | $10.3M | $11.0M | ||
| Q2 24 | $-2.5M | $1.0M | ||
| Q1 24 | $17.6M | $11.2M |
自由现金流CAREPBYI
| Q4 25 | $31.8M | $14.4M | ||
| Q3 25 | $10.3M | $9.7M | ||
| Q2 25 | $7.7M | $14.1M | ||
| Q1 25 | $4.9M | $3.6M | ||
| Q4 24 | $28.8M | $15.6M | ||
| Q3 24 | $8.4M | $11.0M | ||
| Q2 24 | $-4.3M | $1.0M | ||
| Q1 24 | $16.3M | — |
自由现金流率CAREPBYI
| Q4 25 | 79.9% | 19.1% | ||
| Q3 25 | 26.3% | 17.7% | ||
| Q2 25 | 20.6% | 26.8% | ||
| Q1 25 | 13.1% | 7.7% | ||
| Q4 24 | 83.5% | 26.4% | ||
| Q3 24 | 24.6% | 13.7% | ||
| Q2 24 | -12.7% | 2.1% | ||
| Q1 24 | 48.8% | — |
资本支出强度CAREPBYI
| Q4 25 | 20.2% | 0.0% | ||
| Q3 25 | 3.9% | 0.0% | ||
| Q2 25 | 5.1% | 0.0% | ||
| Q1 25 | 4.1% | 0.1% | ||
| Q4 24 | 23.6% | 0.0% | ||
| Q3 24 | 5.5% | 0.0% | ||
| Q2 24 | 5.4% | 0.0% | ||
| Q1 24 | 3.9% | 0.0% |
现金转化率CAREPBYI
| Q4 25 | — | — | ||
| Q3 25 | 2.18× | 1.10× | ||
| Q2 25 | 1.13× | 2.41× | ||
| Q1 25 | 0.71× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.83× | 0.54× | ||
| Q2 24 | -0.51× | — | ||
| Q1 24 | 3.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
